jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

June. 30, 2021

July. 22, 2024

jRCT2071210039

The Comparative Pharmacokinetic Study of OP-2024 in Healthy Male Volunteers

OP-2024-001 Study

Taguchi Fumi

OHARA Pharmaceutical Co.,Ltd.

36F St.Luke's Tower 8-1, Akashi-cho, Chuo-ku, Tokyo, Japan

+81-3-6740-7701

chiken@ohara-ch.co.jp

Department of Clinical Development

OHARA Pharmaceutical Co.,Ltd.

36F St.Luke's Tower 8-1, Akashi-cho, Chuo-ku, Tokyo, Japan

+81-3-6740-7701

chiken@ohara-ch.co.jp

Complete

July. 20, 2021

July. 20, 2021
12

Interventional

non-randomized controlled trial

open(masking not used)

active control

crossover assignment

other

1) Healthy Japanese male.
2) Those with age >= 20 to <= 40 years.
3) Those with BMI >= 18.5 to < 25.0.
4) Those who have provided voluntary written consent to participate in the study.

1) Those with a history of allergies to investigational drug ingredients, drugs, or foods
2) Those who are undergoing treatment for, or have a history of, respiratory, circulatory, central nervous system, gastrointestinal, hepatic, renal, hematopoietic, or endocrine disorders that affect pharmacokinetics
3) Other protocol defined exclusion criteria could apply

20age old over
40age old under

Male

Parkinson's disease

Oral administration of OP-2024 (1 capsule) or control (1 tablet).

Pharmacokinetics

Safety

OHARA Pharmaceutical Co.,Ltd.
Hakata Clinic Institutional Review Board
6-18, Tenyamachi, Hakata-ku, Fukuoka-shi, Fukuoka

+81-92-283-7701

Approval

June. 18, 2021

No

none

History of Changes

No Publication date
4 July. 22, 2024 (this page) Changes
3 Dec. 12, 2021 Detail Changes
2 July. 29, 2021 Detail Changes
1 June. 30, 2021 Detail